Reimagine API sourcing with us— efficient, effortless, future-proof.
24-26 June 2025
SNIEC, Shanghai, ChinaOur Team at CPHI China 2025
Deepak Sapra
CEO, Pharmaceutical Services And Active Ingredients
Nirav Shah
Vice President, and Head, API - North Asia
Kundan Reddy
Director, API Sales & Marketing - China
Tammy Tang
Director, API Sales & Marketing - China
Jayce Yang
Associate Director, API Sales & Marketing - China
Rohan Kaushik
Associate Vice President, API - BD & Portfolio
Siddhartha Deshpande
Associate Vice President, API Sales & Marketing, SEAMEA
Susmit Dey
Sales & Marketing API & B2B formulations, SSEA
Ankur Singh
Director, Business Development & Growth Initiatives
Devang Srivastava
Associate Director, Korea & Hong Kong
Ashwinikumar Kulkarni
Vice President & Global Head - Demand Planning, Customer Support & Program Management
E Sreedhar
Executive Vice President, API Regulatory Affairs
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 250+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
-
250+ APIs
-
8 Manufacturing sites
-
1970+ drug master files across global markets.
-
Over 325 ANDAs
-
Filed 4500+ patents globally, out of which 1125 have been granted.
-
Experience with complex APIs and formulations supporting early market entries.
-
Preferred pharma API supplier for pharma companies in more than 80 countries.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
What we achieved in the past year:
Our Achievement (awards)
25/04/2024
USP recognized Dr. Reddy’s with a crystal award for significant contribution towards “New and modernized monograph submissions”
05/04/2024
Dr. Reddys Strategic collaboration with Industrial Promotion Services (IPS) to support the East African Combined Pharmaceutical Center (EACPC) in Kenya
05/12/2023
Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma
15/02/2023
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row
15/02/2023
S&P Global’s Sustainability Yearbook for the 3rd year
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
05/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2019
Our Plants
About CPHI China 2025
This premier event brings together over 3,500+ exhibiting companies, 90,000+ pharma professionals, and the latest innovations across pharmaceutical ingredients, contract manufacturing, biopharma, packaging, drug delivery systems, and more. It's where key industry players meet to explore new opportunities, deepen existing partnerships, and stay ahead of fast-evolving market demands.
As part of this dynamic ecosystem, we’re looking forward to engaging with peers, partners, and potential collaborators. Whether you're looking to streamline your API sourcing, improve supply chain efficiency, or explore strategic synergies—we’re open to conversations that create value.
If you're attending CPHI China, we’d love to connect.Let’s discuss how we can support your growth with smarter, simpler, and future-ready sourcing solutions.
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.
Let’s discuss API sourcing
Join us at Hall - 9.1 | Booth - B48